- recruitingPHASE1, PHASE2
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
This study looks at a new drug, AZD3470, alone or with other cancer medicines, for people with blood cancers like lymphoma. It aims to see if it's safe, how it works, and if it helps shrink the cancer. This is an early-stage trial.
United States · Australia · Brazil - recruitingPHASE1, PHASE2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
This study is testing a new drug, CCS1477 (also called inobrodib), for people with certain blood cancers like lymphoma, myeloma, or leukaemia. It aims to see if the drug is safe, well-tolerated, and how it works in the body.
United States · France · Spain - recruitingPHASE4
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
This study is for people in the UK who are already taking part in a trial for a cancer medicine called pirtobrutinib. It's looking at how safe and effective the medicine is in the long term for chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
United States · Australia · France - recruitingPHASE1
Study of SGR-1505 in Mature B-Cell Neoplasms
This study is testing a new medicine called SGR-1505 for certain types of B-cell lymphoma. We want to find out if it's safe, what dose works best, and if it can help slow down the disease. It's for people whose treatment hasn't worked or stopped working.
United States · France · Italy - recruitingPHASE2
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
This study looks at adding a new drug, ibrutinib, to usual treatment for a type of brain lymphoma called PCNSL. It aims to see if this combination can better stop the cancer from growing or spreading in people who can't have a stem cell transplant.
Canada - recruitingPHASE2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
This study looks at a new drug, epcoritamab, combined with other cancer medicines, for adults with Non-Hodgkin Lymphoma. It aims to see how safe these combinations are and if they help reduce the disease. Epcoritamab is given as an injection under the skin.
United States · China · Czechia - active not recruitingPHASE1
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
This study is looking at a new medicine called epcoritamab for children and young adults (up to 25) with a type of Non-Hodgkin Lymphoma. It aims to see if the medicine is safe and how well it's tolerated when given by injection for lymphoma that has come back or hasn't responded to other treatments.
United States · Australia · Belgium - recruitingPHASE1, PHASE2
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
This study is testing a new medicine called BGB-16673 for people with certain types of B-cell cancers, like lymphoma or chronic leukaemia. It aims to find the right dose and see how well it works and if it's safe. It's an early-stage trial.
United States · Australia · Brazil - recruitingPHASE4
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
This study looks at the long-term safety of a medicine called pirtobrutinib for chronic lymphocytic leukemia and non-Hodgkin lymphoma. It's for people who have already been in other pirtobrutinib studies and want to continue their treatment or follow-up.
United States · Australia · France - recruitingPHASE1, PHASE2
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
This study is testing two medicines, KRT-232 and acalabrutinib, together for people with certain types of lymphoma or leukaemia that have come back or not responded to previous treatments. Researchers want to see if this combination is safe and works well.
United States · Australia · Belgium - recruitingPHASE2
Methods of T Cell Depletion Trial (MoTD)
This study compares different ways to prevent a complication called GvHD after stem cell transplants for various blood cancers. It's looking for the best treatment plan to help patients recover well, using common medicines like Thymoglobulin, Cyclophosphamide, Cyclosporine, Sirolimus, and Mycophenolate Mofetil.
United Kingdom - active not recruitingPHASE1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
This study is testing new combinations of medicines for a type of blood cancer called Non-Hodgkin Lymphoma. It aims to see how safe and effective these new treatments are, and how the body handles them. It's for people whose cancer hasn't responded well to previous treatments.
United States · Israel · Italy - authorisedPhase I and Phase II (Integrated)- Other
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK‑1045 Monotherapy or in Combination with Other Anticancer Agents in Participants with Non-Hodgkin Lymphoma
This study is testing a new drug, MK-1045, alone or with other treatments, for Non-Hodgkin Lymphoma. Researchers want to see if it's safe and if it helps shrink the cancer. It includes both early safety tests and checking how well it works.
Poland · Italy · France